T-cell engager therapy

Business news, market intelligence, and global industry analysis.

The Latest

Samsung Galaxy M17 5G review: Is this budget Samsung phone worth buying at ₹15,498?

Samsung Galaxy M17 5G at ₹15,498: Hidden budget beast or just another overhyped Samsung phone?

Representative image of a Boeing C-17 Globemaster III during maintenance, illustrating Boeing’s $166.8 million landing gear spares contract modification and the growing strategic importance of military airlift sustainment.

Why Boeing’s $166.8 m C-17 spares win could matter more than it looks for BA stock

Why selective immune homeostasis is the bigger story behind CUE-401

Nida Khan in TCS Nashik case: Designation disputed, pregnancy cited for bail, police deploy four teams in ongoing manhunt

Antengene deepens oncology ambitions with three next-generation ADC and T-cell engager programs at AACR 2026

Discover how Antengene Corporation Limited’s AACR 2026 oncology presentations could reshape its pipeline strategy and investor outlook. Read the full analysis.

μFR system
αvβ6-integrin
α4β7 integrin
ZYUS Life Sciences
Zyrtec
Zyprexa Zydis
Zynga
Zynext Ventures USA LLC
Zynext Ventures
Zynex

March 18, 2026